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BACKGROUND
SUMMARY & CONCLUSIONS
The pathogenesis of infection in patients with end stage liver disease remains poorly understood (Bonnel et al. Clin
Gastroenterol Hepatol 2011). Translocation of gut bacteria may play a pivotal role. Defensins are natural antimicrobial
peptides with activity against a wide range of microorganisms. In humans, α-defensins are secreted by PMNs (HNP-1 to -4) or
Paneth cells (HD-5 and HD-6), whereas β-defensins are broadly expressed (Ganz. Nature Rev Immunol, 2003). Localization of
α- and β-defensins to the small and large intestinal epithelium indicates a role of these proteins in the defense against
systemic translocation of commensal bacteria (Wehkamp et al. Nature Clin Pract Gastroenterol Hepatol, 2005). The potential
involvement of deficiencies in the system of natural antimicrobial peptides (circulating and intestinal) in increased
susceptibility of cirrhotic patients to infection has not been explored yet.
Figure 1. Plasma concentrations of hBD-1 and hBD-2 are significantly elevated in patients with viral hepatitis and cirrhosis.  hBD-1 and 
hBD-2 concentrations in plasma samples were measured by ELISA.  hBD-1 levels were  higher in patients with chronic viral hepatitis  
(N=23, median, 95%CI, 1.35, 1.26-1.87 ) or cirrhosis (N= 15, 1.44, 1.2-1.57)  than in controls (N=13, 0.84, 0.75-1.138) (P=0.003, 
Kruskal-Wallis test).  Similarly, hBD-2 concentration was significantly increased in chronic viral hepatitis  (N= 19, 0.24, 0.14-0.43 ) or 
cirrhosis (N=18, 0.21, 0.08-0.74) compared with healthy controls (N=11, 0.04, 0.03-0.08) (P=0.028).
Figure 2. Etiology of chronic liver disease does not affect plasma
concentration of hBD-1 and hBD-2. Plasma concentration of hBD-1 and hBD-
2 was measured by ELISA in various subgroups of patients with chronic liver
disease. The red dotted lines indicate the mean plasma concentration of hBD-
1 and hBD-2 in the respective healthy controls.
Figure 3. hBD-1 and hBD-2 proteins are detected in ascitic fluid of
patients with cirrhosis. Ascites was obtained after peritoneal puncture
of patients (n=5) with cirrhosis and hBD-1 and hBD-2 concentrations
were detected by ELISA. Plasma samples of the same individuals were
concomitantly obtained and tested for hBD-1 and hBD-2. Bars
represent mean + sdv. (hBD-1: plasma: 1.39 ± 0.36 ng/ml, ascites:
1.62 ± 0.53 hBD-2: plasma: 0.36 ± 0.29, ascites:0.27 ± 0.22).
Figure 4. Positive correlation of LBP and hBD-2 in peripheral blood of
cirrhotic patients. LBP and hBD-2 concentrations were measured in the sera
of individual patients with cirrhosis. Correlation analysis revealed a
significant association between values of the two markers.
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AIM OF THE STUDY
 Plasma levels of hBD-1 and hBD-2 are significantly elevated in patients with chronic viral hepatitis and cirrhosis,
independent of the underlying cause of liver disease.
 Both hBD-1 and hBD-2 are detected in the ascitic fluid of patients with cirrhosis.
 Elevated circulating -defensins may be indicative of increased bacterial translocation as shown by the positive
association between serum hBD2 and LBP.
Table 1. Characteristics of  the  patient population 
Hepatitis Cirrhosis
Patients (N) 24 22
Age (years, average ±SD,range) 43.5 ± 13 (26-65) 62.1 ± 11.7 (51-89)
Male 18 19
HBV -related 12 3
HCV - related 12 5
Alcohol - related 12
Unknown etiology 2
TBil (average±SD,range) 0.7 ± 0.42 (0.2-1.7) 3.57 ± 3.9 (0.32-15.73)
Crea (average±SD,range) 0.85  ± 0.15 (0.6-1.1) 1.04  ± 0.47 (0.6-2.5)
Meld score (average±SD,range) 15.9 ± 5.7 (8-25)
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Figure 5. Bacterial DNA is not detected in the sera of cirrhotic patients,
possibly due to a threshold limitation. 5a, Total DNA was extracted
from the serum of patients with cirrhosis and bacterial 16s ribosomal
DNA (rRNA) was amplified by use of universal primers (F: 5’-
AGAGTTTGATCATGGCTCAG-3’ and R:5’-ACCGCGACTGCTGCTGGCAC-
3’). L1, 50 bp DNA ladder, L2, negative control, L3, positive control,
culture of S.aureus (540bp), L4-6, cirrhotic patients. 5b, Total DNA
was extracted from serial dilutions of cultured S.aureus. Results
indicate a threshold (15.8 pg/ul) for the detection of bacterial DNA.
PATIENTS AND METHODS
L1  L2   L3  L4   L5 L6
The aim of the present study was to determine the serum protein content for human defensin β1 (hBD-1) and β2 (hBD-2) in
patients with chronic liver disease and associate their expression to markers of systemic bacterial translocation.
Plasma was obtained from 24 patients with chronic viral hepatitis, 22 with decompensated cirrhosis, and 13 healthy controls.
Demographic, clinical, and laboratory information is shown in Table 1.
Enzyme-linked Imunosorbent assays (ELISA) were used for the measurement of plasma concentrations of hBD-1 and hBD-2
(antibodies from Peprotech, UK) and lipopolysaccharide-binding protein/LBP (commercial kit from USCN, China).
Statistical analysis was performed with the GraphPad statistical software.
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